99锝-亚甲基二磷酸盐治疗原发性骨质疏松症的疗效初探

The clinical efficacy of 99Tc-MDP on primary osteoporosis

目的探讨99锝-亚甲基二磷酸盐治疗原发性骨质疏松症的疗效及安全性。方法原发性骨质疏松症患者112例,随机分为治疗组及对照组,治疗组给予99锝-亚甲基二磷酸盐治疗,对照组给予阿法骨化醇治疗,疗程均1个月,检测及评价治疗前后临床症状、血清骨特异性碱性磷酸酶水平及骨密度变化。结果临床症状改善:治疗组有效率89.29%(50/56),对照组有效率67.31%(35/56),两组比较P<0.05有统计学意义。血清BALP下降、治疗组优于对照组(P<0.05),骨密度增高治疗组优于对照组(P<0.05)。结论 99锝-亚甲基二磷酸盐可抑制骨吸收、促进骨生成,增加骨密度,改善骨质疏松症,提高患者生活质量,值得临床推广。

Objective To investigate the clinical efficacy and safety of 99Tc-MDP on primary osteoporosis. Methods A total of 112 patients with primary osteoporosis were selected and randomly divided into treatment group and control group. Patients in treatment group were treated with 99Tc - MDP, while patients in control group were treated with alfacalcidol. The whole treatment lasted for 1 month. The clinical manifestations before and after the treatment were observed and evaluated. The changes of serum BALP and bone mineral density （BMD） were also observed. Results The effective rate in treatment group and control group was 89.29% （50/56） and 67.31% （35/56）, respectively. And the difference between the two groups was significant （P 〈 0. 05 ）. The serum BALP in treatment group decreased more significantly than that in control group （ P 〈 0.05 ）. BMD in treatment group increased more significantly than that in control group （P 〈 0. 05）. Conclusion 99Tc-MDP can inhibit bone resorption, promote bone formation, increase BMD, relieve osteoporosis, and improve the quality of patients＇ life. So, it is worthy of wide promotion in clinical work.